Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
NCT06630585Phase 3Recruiting
- Sponsor
- University of Bern
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 1 diabetes mellitus (T1D) comparing Standard of Care with Standard of Care + Tirzepatide (2 arms). Primary endpoint: Time in Range (3.9-10.0 mmol/L) at 16 weeks. Started Feb 2025; status: recruiting.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06630585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630585.